SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported) October
25, 2005
CHEMBIO
DIAGNOSTIC, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
0-30379
|
|
88-0425691
|
(State
or other jurisdiction
|
|
(Commission
File Number)
|
|
(IRS
Employer
|
of
Incorporation)
|
|
|
|
Identification
Number)
|
|
|
3661
Horseblock Road
|
|
|
|
|
Medford,
NY 11763
|
|
|
|
|
(Address
of principal executive offices)
|
|
|
|
|
631-924-1135
|
|
|
|
|
(Registrant’s
Telephone Number)
|
|
|
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
7.01. Regulation FD Disclosures.
(a) |
Included
herein as exhibit 99.1 and hereby incorporated by reference is
an
investment report paid for by the registrant, as indicated in the
report.
|
(b) |
On
October 27, 2005 the Registrant issued the press release titled
“Chembio
Partners with Pfizer in Combating AIDS in Africa” included herein as
Exhibit 99.2 and hereby incorporated by
reference.
|
ITEM
9.01. Financial Statements and Exhibits
(c) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date: October 27, 2005
Chembio
Diagnostics, Inc.
By:
/s/
Lawrence A. Siebert
Lawrence
A. Siebert
Chief
Executive Officer